DE69805305D1 - Verwendung von phanquinon zur behandlung von alzheimer's krankheit - Google Patents

Verwendung von phanquinon zur behandlung von alzheimer's krankheit

Info

Publication number
DE69805305D1
DE69805305D1 DE69805305T DE69805305T DE69805305D1 DE 69805305 D1 DE69805305 D1 DE 69805305D1 DE 69805305 T DE69805305 T DE 69805305T DE 69805305 T DE69805305 T DE 69805305T DE 69805305 D1 DE69805305 D1 DE 69805305D1
Authority
DE
Germany
Prior art keywords
alzheimer
disease
treatment
phanquinon
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69805305T
Other languages
English (en)
Other versions
DE69805305T2 (de
Inventor
Michel Xilinas
Nikolas Gerolymatos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PN Gerolymatos SA
Original Assignee
PN Gerolymatos SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PN Gerolymatos SA filed Critical PN Gerolymatos SA
Publication of DE69805305D1 publication Critical patent/DE69805305D1/de
Application granted granted Critical
Publication of DE69805305T2 publication Critical patent/DE69805305T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DE69805305T 1997-08-21 1998-07-17 Verwendung von phanquinon zur behandlung von alzheimer's krankheit Expired - Fee Related DE69805305T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR97100330 1997-08-21
GR97100507 1997-12-31
PCT/IB1998/001095 WO1999009981A1 (en) 1997-08-21 1998-07-17 Use of phanquinone for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
DE69805305D1 true DE69805305D1 (de) 2002-06-13
DE69805305T2 DE69805305T2 (de) 2002-12-05

Family

ID=26316681

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69805305T Expired - Fee Related DE69805305T2 (de) 1997-08-21 1998-07-17 Verwendung von phanquinon zur behandlung von alzheimer's krankheit

Country Status (25)

Country Link
US (2) US6670369B1 (de)
EP (1) EP1007040B1 (de)
JP (1) JP2001513558A (de)
CN (1) CN1145482C (de)
AT (1) ATE217191T1 (de)
AU (1) AU741782B2 (de)
BG (1) BG64300B1 (de)
BR (1) BR9814945A (de)
CA (1) CA2301706C (de)
CZ (1) CZ299739B6 (de)
DE (1) DE69805305T2 (de)
DK (1) DK1007040T3 (de)
EA (1) EA002526B1 (de)
ES (1) ES2177024T3 (de)
HK (1) HK1029937A1 (de)
HU (1) HUP0004331A3 (de)
IL (1) IL134263A (de)
IS (1) IS1910B (de)
NO (1) NO317770B1 (de)
NZ (1) NZ502565A (de)
PL (1) PL191208B1 (de)
PT (1) PT1007040E (de)
SK (1) SK284708B6 (de)
TR (1) TR200000455T2 (de)
WO (1) WO1999009981A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
DK1140090T3 (da) * 1999-01-07 2005-04-18 Gerolymatos P N Sa Anvendelse af phanquinon til behandlingen eller hindringen af hukommelsessvigt
AU2001250573A1 (en) * 2000-04-28 2001-11-12 Michel Xilinas Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone
AU2001250571A1 (en) * 2000-04-28 2001-11-12 P.N. Gerolymatos S.A. Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol
JP2004506915A (ja) 2000-08-18 2004-03-04 ザ　ゼネラル　ホスピタル　コーポレーション 白内障を阻害又は促進する物質を同定する方法及びその使用
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
DE602004023823D1 (de) * 2003-03-11 2009-12-10 Kaneka Corp Öl-in-wasser-emulsion, die coenzym q10 enthält, und verfahren zu ihrer herstellung
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
PL3137093T3 (pl) * 2014-04-29 2018-06-29 Affiris Ag Leczenie i profilaktyka choroby Alzheimera (AD)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617417A1 (de) * 1966-12-08 1971-03-25 Ciba Geigy Pharmazeutisches Praeparat
DE1804736A1 (de) 1967-11-02 1969-06-26 Ciba Geigy Pharmazeutisches Praeparat
IL40311A (en) 1972-09-06 1973-04-30 Pharmaplantex Ltd Pharmaceutical preparation for the treatment of gastro-intestinal troubles containing phanquone and furazolidone
GB1472257A (en) 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4981844A (en) * 1988-10-04 1991-01-01 University Of Cincinnati Method to improve immune response and resistance to infection following surgery by diet composition
US5091391A (en) 1990-08-16 1992-02-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2078019C (en) * 1991-09-13 2002-08-27 Siegbert Heinrich Bissbort Substance or composition and uses thereof
DE69227380T3 (de) 1991-11-12 2007-01-11 Prana Biotechnology Ltd., South Melbourne Verfahren zur bestimmung und behandlung von alzheimer-krankheit
GB9126874D0 (en) * 1991-12-18 1992-02-19 Wellcome Found Medicaments
EP0713392A1 (de) * 1994-05-11 1996-05-29 P.N. Gerolymatos S.A. VERWENDUNG VON CLIOQUINOL ZUR BEHANDLUNG DER DURCH HELICOBACTER - z.B. H. PYLOZI - VERURSACHTEN INFEKTIONEN UND ÄNLICHEN KRANKHEITEN
WO1997046526A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
ES2162319T3 (es) 1996-08-13 2001-12-16 Gerolymatos P N Sa Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
EP1007048A4 (de) 1997-03-11 2004-09-22 Gen Hospital Corp Identifizierung von mitteln zur behandlung der alzheimerischen krankheit
US5980882A (en) 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US5980914A (en) 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US5994323A (en) 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
DK1140090T3 (da) 1999-01-07 2005-04-18 Gerolymatos P N Sa Anvendelse af phanquinon til behandlingen eller hindringen af hukommelsessvigt
AU2001250573A1 (en) 2000-04-28 2001-11-12 Michel Xilinas Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using phanquinone
AU2001250571A1 (en) 2000-04-28 2001-11-12 P.N. Gerolymatos S.A. Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol

Also Published As

Publication number Publication date
EP1007040A1 (de) 2000-06-14
US20050003018A1 (en) 2005-01-06
JP2001513558A (ja) 2001-09-04
CZ299739B6 (cs) 2008-11-05
NO20000771L (no) 2000-04-25
EP1007040B1 (de) 2002-05-08
EA200000242A1 (ru) 2000-08-28
BR9814945A (pt) 2000-09-05
CN1267218A (zh) 2000-09-20
HK1029937A1 (en) 2001-04-20
NZ502565A (en) 2002-03-01
DE69805305T2 (de) 2002-12-05
EA002526B1 (ru) 2002-06-27
ES2177024T3 (es) 2002-12-01
CZ2000611A3 (cs) 2000-08-16
BG104179A (en) 2000-10-31
NO317770B1 (no) 2004-12-13
NO20000771D0 (no) 2000-02-16
DK1007040T3 (da) 2002-08-26
WO1999009981A1 (en) 1999-03-04
SK2062000A3 (en) 2000-08-14
CN1145482C (zh) 2004-04-14
US7629354B2 (en) 2009-12-08
IS5366A (is) 2000-01-28
PT1007040E (pt) 2002-10-31
IL134263A0 (en) 2001-04-30
AU8124198A (en) 1999-03-16
PL191208B1 (pl) 2006-03-31
BG64300B1 (bg) 2004-09-30
CA2301706C (en) 2005-10-04
TR200000455T2 (tr) 2000-09-21
IL134263A (en) 2006-04-10
PL338673A1 (en) 2000-11-20
ATE217191T1 (de) 2002-05-15
IS1910B (is) 2003-12-31
HUP0004331A3 (en) 2001-09-28
AU741782B2 (en) 2001-12-06
US6670369B1 (en) 2003-12-30
CA2301706A1 (en) 1999-03-04
HUP0004331A2 (hu) 2001-05-28
SK284708B6 (sk) 2005-09-08

Similar Documents

Publication Publication Date Title
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE69625691T2 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69420229T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
BR0012921A (pt) Compostos calcilìticos
DE689838T1 (de) Verwendung von Diademosim 5',5'''-p1,p4-Tetraphosphat zur Behandlung von ischämischen Myokard-Erkrankungen
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE230608T1 (de) Verwendung von bradykinin-antagonisten zur herstellung von arzneimitteln zur behandlung und prävention der alzheimer'schen krankheit
ATE195072T1 (de) Verwendung von 6,7-substituierten-2- aminotetraline zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von septischem schock, und antipyretischer und antientzündlicher zusammensetzungen
DE69421705T2 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE69404370T2 (de) Gelatinase A zur Behandlung von der Alzheimerschen Krankheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee